title: [Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
abstract: We have experienced 56 cases of advanced and recurrent colorectal carcinoma treated with 5-Fluorouracil (5-FU)/l-Leucovorin (LV) therapy from January 2000 to March 2005. The RPMI regimen was employed, but 5-FU was administered at the dose of 500 mg/body for the first cycle and 750 mg/body for subsequent cycles, thanks to its safety, economy, and simplicity. l-LV was administered at 375 mg/body for all cycles. An average of 3.6 cycles were given, and the average 5-FU dose was 427.7 mg/m(2). The probability of the toxicities (Grade 3 or 4) tended to be less frequent compared with that observed in multi-center cooperative studies in Japan, although the frequency of nausea and vomiting was similar. Responses were CR 0/56, PR 16/56, NC 23/56, and PD 17/56, and the overall response rate was 28.6%. The median progression-free survival time was 6.0 months, and the median overall survival time was 14.0 months, which was longer than that achieved in multi-center studies in Japan. These data suggest that new regimens such as FOLFOX 4 and infusional 5-FU/l-LV therapy can be administered at lower doses of anti-cancer drugs with less toxicity and possible longer survival time.
authors.affiliation: Dept. of Surgery, Seirei Mikatahara General Hospital.
authors.forename: Takeru
authors.initials: T
authors.lastname: Matsuda
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ogino
authors.forename: Motoki
authors.initials: M
authors.lastname: Hiroyoshi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Fujita
authors.forename: Takashi
authors.initials: T
authors.lastname: Itoh
authors.forename: Hirochika
authors.initials: H
authors.lastname: Toyama
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kawai
authors.forename: Daisuke
authors.initials: D
authors.lastname: Makita
authors.forename: Kozo
authors.initials: K
authors.lastname: Tsunemi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Moritomo
authors.forename: Tetsu
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D002955:Leucovorin; D005472:Fluorouracil